Engineered proteins from transgenic animals

描述（由申请人提供）：生物技术行业正在开发的产品中约有25%是抗体，其中许多抗体针对人体细胞和组织上的表位。我们提出了一个新的概念，用于生产具有治疗潜力的抗体，这是基于蛋白质-蛋白质相互作用的最新进展和转基因技术的最新发展。这个概念的实施将避免许多昂贵和耗时的修饰，这些修饰在鉴定出潜在的治疗性单克隆抗体之后经常需要，以便优化它们的药理学性质并使它们适合于大规模生产。通过将来自体外研究的最新数据与对基因组学的新生理解相结合，我们将扩大可以获得的表位范围，从而扩大潜在治疗性抗体的范围。

DESCRIPTION (provided by applicant): Approximately 25% of the products being developed by the biotechnology industry are antibodies and many of these antibodies are directed to epitopes on human cells and tissues. We are proposing a novel concept for the production of antibodies with therapeutic potential that is based on recent advances in protein-protein interactions and recent developments in transgenic technology. Execution of this concept will obviate many of the expensive and time consuming modifications that are frequently required after potentially therapeutic monoclonal antibodies are identified in order to optimize their pharmacological properties and to make them amenable to large scale production. By combining recent data derived from in vitro studies with the nascent understanding of genomics, we will extend the range of epitopes that can be accessed and, therefore, extend the range of potentially therapeutic antibodies.